ERBB2 and breast cancer: In this work, we show that adjuvant ET with AI is superior to TAM or TAM-AI in terms of DFS for patients with HR-positive/HER2-positive BC receiving adjuvant anthracycline/taxane-based chemotherapy combined with trastuzumab.